|Dr. Peter P. Luo Ph.D.||Co-Founder, CEO & Chairman||N/A||N/A||1966|
|Mr. Man Kin Tam M.B.A.||CFO & Director||N/A||N/A||1977|
|Dr. Fangyong Du Ph.D.||Chief Technology Officer||N/A||N/A||1970|
|Dr. Jc Xu M.D., Ph.D.||Chief Scientific Officer||N/A||N/A||1965|
|Ms. Ami Celeste Knoefler||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. Ling Zhou||Head of HR||N/A||N/A||N/A|
|Dr. Qinghai Zhao||Chief Manufacturing Officer||N/A||N/A||1961|
|Ms. Yan Li M.B.A.||Sr. VP of Bioinformatics & Information Technology||N/A||N/A||1975|
|Ms. Xiaohong She||Sr. VP & Head of Clinical Operations||N/A||N/A||1967|
|Dr. Guizhong Liu Ph.D.||Head of Biology & Pharmacology||N/A||N/A||1971|
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Adagene Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.